{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T08:40:00Z","timestamp":1791016800798,"version":"4.1.0"},"reference-count":19,"publisher":"American Association for Cancer Research (AACR)","issue":"4","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The success of molecularly targeted agents, such as imatinib, has led to expectations of a new era in anticancer drug development, and to a greatly increased focus on targeting as a strategy. However, the number of successes to date is small, and recent results suggest that the success of imatinib, for instance, in treating chronic myelogenous leukemia and gastrointestinal stromal tumor may be the exception rather than the rule. Here, we argue that the search for new anticancer agents needs to continue on as many fronts as possible, and not be focused on one strategy alone. [Cancer Res 2009;69(4):1259\u201362]<\/jats:p>","DOI":"10.1158\/0008-5472.can-08-3786","type":"journal-article","created":{"date-parts":[[2009,2,11]],"date-time":"2009-02-11T16:35:04Z","timestamp":1234370104000},"page":"1259-1262","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":134,"title":["Is Anticancer Drug Development Heading in the Right Direction?"],"prefix":"10.1158","volume":"69","author":[{"given":"Trevor W.","family":"Hambley","sequence":"first","affiliation":[{"name":"School of Chemistry, The University of Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2009,2,12]]},"reference":[{"key":"2022061701333750800_B1","doi-asserted-by":"crossref","unstructured":"Collins I, Workman P. New approaches to molecular cancer therapeutics. Nat Chem Biol\u20082006; 2: 689\u2013700.","DOI":"10.1038\/nchembio840"},{"key":"2022061701333750800_B2","doi-asserted-by":"crossref","unstructured":"Workman P. Genomics and the second golden era of cancer drug development. Mol Biosyst\u20082005; 1: 17\u201326.","DOI":"10.1039\/b501751n"},{"key":"2022061701333750800_B3","doi-asserted-by":"crossref","unstructured":"Hutchinson E. Stressed out hearts. Nat Rev Drug Disc\u20082006; 5: 720.","DOI":"10.1038\/nrd2142"},{"key":"2022061701333750800_B4","doi-asserted-by":"crossref","unstructured":"Hayden EC. Cancer complexity slows quest for cure. Nature\u20082008; 455: 148.","DOI":"10.1038\/455148a"},{"key":"2022061701333750800_B5","unstructured":"Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science\u20082008; 321: 1801\u20136."},{"key":"2022061701333750800_B6","doi-asserted-by":"crossref","unstructured":"Network TCGAR. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature\u20082008; 455: 1061\u20138.","DOI":"10.1038\/nature07385"},{"key":"2022061701333750800_B7","unstructured":"Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science\u20082008; 321: 1807\u201312."},{"key":"2022061701333750800_B8","doi-asserted-by":"crossref","unstructured":"Abbenante G, Reid RC, Fairlie DP. \u201cClean\u201d or \u201cdirty\u201d\u2014just how selective do drugs need to be? Aust J Chem\u20082008; 61: 654\u201360.","DOI":"10.1071\/CH08186"},{"key":"2022061701333750800_B9","doi-asserted-by":"crossref","unstructured":"Jones D, Thomas D, Yin CC, et al. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer\u20082008; 113: 985\u201394.","DOI":"10.1002\/cncr.23666"},{"key":"2022061701333750800_B10","doi-asserted-by":"crossref","unstructured":"Failes TW, Cullinane C, Diakos CI, Yamamoto N, Lyons JG, Hambley TW. Studies of a Co(III) complex of the MMP inhibitor marimastat: a potential hypoxia activated prodrug. Chem Eur J\u20082007; 13: 2974\u201382.","DOI":"10.1002\/chem.200601137"},{"key":"2022061701333750800_B11","doi-asserted-by":"crossref","unstructured":"Kelland LR. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer\u20082007; 7: 573\u201384.","DOI":"10.1038\/nrc2167"},{"key":"2022061701333750800_B12","doi-asserted-by":"crossref","unstructured":"Hambley TW. Physiological targeting to improve anticancer drug selectivity. Aust J Chem\u20082008; 61: 647\u201353.","DOI":"10.1071\/CH08180"},{"key":"2022061701333750800_B13","doi-asserted-by":"crossref","unstructured":"Denny WA. The design of drugs that target tumour hypoxia. Aust J Chem\u20082004; 57: 821\u20138.","DOI":"10.1071\/CH04051"},{"key":"2022061701333750800_B14","unstructured":"Tannock IF, Lee CM, Tunggal JK, Cowan DSM, Egorin MJ. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res\u20082002; 8: 878\u201384."},{"key":"2022061701333750800_B15","doi-asserted-by":"crossref","unstructured":"Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF. The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res\u20082005; 11: 8782\u20138.","DOI":"10.1158\/1078-0432.CCR-05-1664"},{"key":"2022061701333750800_B16","doi-asserted-by":"crossref","unstructured":"Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer\u20082006; 6: 583\u201392.","DOI":"10.1038\/nrc1893"},{"key":"2022061701333750800_B17","doi-asserted-by":"crossref","unstructured":"Fischbach C, Chen R, Matsumoto T, et al. Engineering tumors with 3D scaffolds. Nat Methods\u20082007; 4: 855\u201360.","DOI":"10.1038\/nmeth1085"},{"key":"2022061701333750800_B18","doi-asserted-by":"crossref","unstructured":"Hall MD, Mellor HR, Callaghan R, Hambley TW. Basis for design and development of platinum(IV) anticancer complexes. J Med Chem\u20082007; 50: 3403\u201311.","DOI":"10.1021\/jm070280u"},{"key":"2022061701333750800_B19","doi-asserted-by":"crossref","unstructured":"Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med\u20082006; 355: 2542\u201350.","DOI":"10.1056\/NEJMoa061884"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/69\/4\/1259\/2620761\/1259.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/69\/4\/1259\/2620761\/1259.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T07:08:46Z","timestamp":1655449726000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/69\/4\/1259\/552752\/Is-Anticancer-Drug-Development-Heading-in-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,12]]},"references-count":19,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2009,2,12]]},"published-print":{"date-parts":[[2009,2,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-08-3786","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,12]]}}}